Daiichi goes to bond market for refinancing

Daiichi Sankyo, Japan's third-largest drugmaker, plans to sell as much as $3.12 billion in bonds to refinance a loan taken for its $5 billion acquisition of Ranbaxy Laboratories. Report

Suggested Articles

More than a year after J&J and Bayer pulled the plug on Xarelto in patients after a rare valve replacement, the pair are still seeking answers.

Novartis hopes to leverage its existing presence in the hematology community to achieve a successful launch of Adakveo.

AstraZeneca's Farxiga is touting its heart failure data in patients with or without diabetes, but results in non-diabetics looks particularly strong.